ArticleInvestigational new drugs2019
An orally antitumor chalcone hybrid inhibited HepG2 cells growth and migration as the tubulin binding agent.
Article in Investigational new drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Azole-Flavonoid Hybrids as Emerging Anticancer Agents: A Bioactivity-Focused Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Synthesis and Study of Substituted Chalcones Combined with Fluoroazobenzenes-New Photoswitches for Application in Biological Systems.Molecules (Basel, Switzerland) · 2026Article
- The Proapoptotic Effect of MB-653 Is Associated with the Modulation of Metastasis and Invasiveness-Related Signalling Pathways in Human Colorectal Cancer Cells.Biomolecules · 2025Article
- New 1,2,3-triazole linked ciprofloxacin-chalcones induce DNA damage by inhibiting human topoisomerase I& II and tubulin polymerization.Journal of enzyme inhibition and medicinal chemistry · 2022Article
- Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents.Molecules (Basel, Switzerland) · 2022Review
- Two Important Anticancer Mechanisms of Natural and Synthetic Chalcones.International journal of molecular sciences · 2022Review
- Recent Advances in Bioactive Flavonoid Hybrids Linked by 1,2,3-Triazole Ring Obtained by Click Chemistry.Molecules (Basel, Switzerland) · 2021Review
- Chalcone Derivatives: Role in Anticancer Therapy.Biomolecules · 2021Review
- Comment on: an orally antitumor chalcone hybrid inhibited HepG2 cells growth and migration as the tubulin binding agent.Investigational new drugs · 2021Article
- The Newly Synthetized Chalcone L1 Is Involved in the Cell Growth Inhibition, Induction of Apoptosis and Suppression of Epithelial-to-Mesenchymal Transition of HeLa Cells.Molecules (Basel, Switzerland) · 2021Article
- Synthesis, Anticancer Assessment, and Molecular Docking of Novel Chalcone-Thienopyrimidine Derivatives in HepG2 and MCF-7 Cell Lines.Oxidative medicine and cellular longevity · 2021Article
- FAM172A affects cell proliferation and apoptosis not by targeting β-tubulin in HepG2 cells.Translational cancer research · 2020Article
- Antiproliferative Effect of Acridine Chalcone Is Mediated by Induction of Oxidative Stress.Biomolecules · 2020Article
- Synthesis of Chalcone Derivatives: Inducing Apoptosis of HepG2 CellsFrontiers in pharmacology · 2019Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver cancer is a kind of high mortality cancer due to the difficulty of early diagnosis. It is necessary to develop the anticancer agents to treat liver cancer. Here, a novel chalcone derivative was synthesized and evaluated for anticancer activity in vitro against liver cancer cell lines (HepG2, SNU-423, SMMC7221, and SNU-398). The chalcone hybrid 9 displayed the antiproliferative effect against HepG2, SNU-423, SMMC7221 and SNU-398 cells with IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.